イビデン＜4062＞ 6793 -357Stock name 21 day closing price ⇒ day-on-day comparison.
TOWA <6315> 10670 -550
Relatively weakened semiconductor-related due to the decline of the US SOX Index.
IBIDEN <4062> 6793 -357
The speed of short-term rise led to profit-taking sales.
Japan Micronics <6871> 6370 -130
Recently rose due to recommendation of new long.
Jigen <3679> 598 -26
Will credit adjustment sales gather due to weekend factors?
Tatuta Densen <5809> 726 -31
The TOB price is pushed up by JX Metals Ltd.'s commencement of tender offer.
Japan Foods <2599> 2334 +400
The TOB price by JAFHD was raised.
Earth Infinity <7692> 120 +12
A stock that is easy to react to tactical movements.
Forcide <2330> 261 +22
Short-term funds are heading towards difficult clues.
ANAP <3189> 388 +21
Follows the good price movement, but no new material separately.
PayCloud <4015> 456 +8
Buy first with upward revision of operating profit forecast for August 24, but deceleration.
ELEMENTS <5246> 1299 +84
Reached a new high of the year on the 20th, and expectations for further increase remain high.
JDSC <4418> 704 -59
Expected to upwardly revise the sales for the June 2024 term, but downwardly revise the operating profit and EBITDA.
TIMS <4891> 234 +11
The first administration of a candidate treatment for acute kidney dysfunction is carried out in the phase 1 clinical trial.
Continue to be viewed as material, but the upside is heavy.
Storage King <2997> 857 +100
Buying popularity continues with two consecutive stop limits until the 20th, but with a long upper shadow.
Exawizards <4259> 351 +14
Starting to entangle from below the 25-day line, the momentum for recovery is increasing.
Circu <7379> 725 +18
Announced a maximum of 480,000 shares of share buyback and purchase commission. Acquired 434,000 shares on the 21st.
Information strategy <155A> 618 +100
Expectations for high price due to breaking through the 25-day line.
DELTA-P <4598> 532 -2
On the announcement of the development status of DFP-17729, I bought ahead on the 20th but stalled.
On the 21st, buying is dominant but the upper limit is heavy.
Helios<4593> 189 -1
Astellas Pharma's subsidiary became popular on the 20th with a licensing agreement but with a long upper wick.
On the 21st, selling is dominant.
